237 related articles for article (PubMed ID: 32876498)
1. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
3. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
4. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging strategies for management of myelodysplastic syndromes.
Saygin C; Carraway HE
Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
Montalban-Bravo G; Garcia-Manero G; Jabbour E
Curr Opin Hematol; 2018 Mar; 25(2):146-153. PubMed ID: 29266015
[TBL] [Abstract][Full Text] [Related]
8. Making the most of hypomethylating agents in myelodysplastic syndrome.
Bhatt G; Blum W
Curr Opin Hematol; 2017 Mar; 24(2):79-88. PubMed ID: 28099273
[TBL] [Abstract][Full Text] [Related]
9. [Novel therapies for higher-risk myelodysplastic syndromes].
Nannya Y
Rinsho Ketsueki; 2018; 59(10):2058-2066. PubMed ID: 30305509
[TBL] [Abstract][Full Text] [Related]
10. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
11. Emerging biological therapies for the treatment of myelodysplastic syndromes.
Zeidan AM; Stahl M; Komrokji R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
[TBL] [Abstract][Full Text] [Related]
12. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
13. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
Roberts DA; Steensma DP
Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
[TBL] [Abstract][Full Text] [Related]
14. Established and emerging targeted therapies in the myelodysplastic syndromes.
Canaani J; Nagler A
Expert Rev Hematol; 2016 Oct; 9(10):997-1005. PubMed ID: 27615383
[TBL] [Abstract][Full Text] [Related]
15. How I treat MDS after hypomethylating agent failure.
Santini V
Blood; 2019 Feb; 133(6):521-529. PubMed ID: 30545832
[TBL] [Abstract][Full Text] [Related]
16. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
17. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
